PRVA

Privia Health Group, Inc. (PRVA) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Privia Health Group, Inc. is a technology-driven, national physician-enablement company operating in 17 markets across the United States. The company utilizes a unique practice model combining regional medical groups with provider autonomy, supported by a proprietary cloud-based technology solution. As of June 30, 2026, the company had 5,644 Implemented Providers and 1.647 million Attributed Lives.

Key Financial Metrics

Liquidity: The company holds $412.2 million in cash and cash equivalents. It maintains a $250 million revolving credit facility (amended May 2026) with no outstanding borrowings as of June 30, 2026.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 21.4% year-over-year (YoY) in Q2 and 23.5% for the six-month period. Growth was driven by a 24.5% increase in Fee-for-Service (FFS) patient care revenue and a 26.0% increase in capitated revenue.
• Profitability Expansion: Operating income surged 252.9% YoY in Q2 to $11.8 million, and Net Income attributable to Privia increased 236.7% to $9.0 million. This was driven by revenue growth outpacing operating expense increases.
• Acquisitions: In May 2026, the company entered the New Jersey market via the acquisition of PMG-NJ (77% interest), contributing to provider and revenue growth. In December 2025, the company acquired an ACO business from Evolent Health, adding over 120,000 attributed lives.
• Effective Tax Rate: The effective tax rate for Q2 2026 was 48.4%, significantly higher than the 32.8% in Q2 2025. This increase was primarily due to unfavorable tax impacts related to equity award vesting and exercise events and Section 162(m) limitations.
• Cash Flow: Net cash used in operating activities was $48.4 million for the six months ended June 30, 2026, compared to $16.1 million in the prior year period, largely due to a $172.4 million increase in accounts receivable.

Guidance, Outlook, and Risks

Outlook: Management expects continued growth in provider base and attributed lives, driving revenue expansion. The company aims to accelerate the transition of markets toward Value-Based Care (VBC) reimbursement models. No specific numerical guidance for the full year 2026 was provided in this text.

Risks and Contingencies:

• Regulatory Inquiry: On March 24, 2026, the company received a "Request for Information or Assistance" from the Department of Health and Human Services' Office of Inspector General (OIG) regarding a single obstetric and gynecological Affiliated Practice in the Mid-Atlantic region concerning medical device procurement. The company is cooperating and does not currently believe this will have a material adverse effect.
• Concentration Risk: Three payers (Payer A, B, and C) accounted for approximately 61% of total revenue in Q2 2026. Payer A alone represented 28% of revenue.
• Operational Risks: Key risks include dependence on relationships with Medical Groups, competition, challenges in new market expansion, and reliance on the athenahealth EMR vendor.

Investor Verification Checklist

• Accounts Receivable Growth: Verify the sustainability of the $172.4 million increase in accounts receivable and its impact on future cash collections.
• Tax Rate Volatility: Assess the impact of equity award vesting on future effective tax rates and net income projections.
• Provider Liability Estimates: Review the actuarial assumptions used for the $541.4 million provider liability balance, particularly regarding at-risk capitated arrangements.
• Acquisition Integration: Monitor the integration progress and financial contribution of the New Jersey (PMG-NJ) and Arizona acquisitions.
• OIG Inquiry Status: Track the outcome of the OIG inquiry regarding the Mid-Atlantic practice to ensure no material penalties or exclusions arise.